Kevin Boyle, Ziopharm Oncology CEO
September 28, 2021 10:22 AM EDTUpdated September 29, 11:01 AM
People
Pharma
Manufacturing

Zio­pharm lays off half its staff af­ter man­u­fac­tur­ing is­sues force de­lays

Max Gelman

Senior Editor

New Zio­pharm CEO Kevin Boyle has on­ly been at the biotech for less than a month, but he’s al­ready en­gi­neer­ing ma­jor changes.

Late Mon­day af­ter­noon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times